Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables: 2019-2024

Historic Receivables for Legend Biotech (LEGN) over the last 6 years, with Dec 2024 value amounting to $7.1 million.

  • Legend Biotech's Receivables fell 7.90% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.4 million, marking a year-over-year decrease of 67.88%. This contributed to the annual value of $7.1 million for FY2024, which is 92.99% down from last year.
  • Legend Biotech's Receivables amounted to $7.1 million in FY2024, which was down 92.99% from $100.8 million recorded in FY2023.
  • In the past 5 years, Legend Biotech's Receivables ranged from a high of $100.8 million in FY2023 and a low of $1.0 million during FY2022.
  • Over the past 3 years, Legend Biotech's median Receivables value was $7.1 million (recorded in 2024), while the average stood at $36.3 million.
  • Its Receivables has fluctuated over the past 5 years, first crashed by 98.97% in 2022, then soared by 9,613.97% in 2023.
  • Over the past 5 years, Legend Biotech's Receivables (Yearly) stood at $75.6 million in 2020, then soared by 32.78% to $100.4 million in 2021, then slumped by 98.97% to $1.0 million in 2022, then skyrocketed by 9,613.97% to $100.8 million in 2023, then plummeted by 92.99% to $7.1 million in 2024.